Abstract. Recent studies have indicated that homeobox A3 (HOXA3) functions as a carcinogen in colon cancer and the methylation level of HOXA3 is significantly increased in lung adenocarcinoma (LUAD) tissues. However, at least to the best of our knowledge, few studies to date have been performed on HOXA3 in non-small cell lung cancer (NSCLC). Therefore, further studies on HOXA3 expression in NSCLC and the potential regulatory mechanisms are urgently required. In this study, HOXA3 expression in 55 tissues of cases of NSCLC and corresponding non-lung cancer tissues was detected by reverse transcription-quantitative PCR (RT-qPCR). In addition, the clinical significance of HOXA3 expression in NSCLC was evaluated using the Cancer Genome Atlas (TCGA) database. Bioinformatics analysis was then performed to elucidate the potential molecular mechanisms of action of HOXA3. Furthermore, the potential target microRNAs (miRNAs or miRs) of HOXA3 were predicted using miRWalk2.0. Based on Gene Expression Omnibus (GEO) and TGCA databases, standardized mean difference (SMD) and sROC methods were used for meta-analyses of the expression of potential target miRNAs of HOXA3 in NSCLC to evaluate their association with HOXA3. The results revealed that the HOXA3
Introduction
The most recent data indicate that lung cancer remains the type of cancer with the highest prevalence among men and women and is also one of the most common causes of cancer-related mortality (1) . Approximately 1.82 million cases of lung cancer are newly diagnosed globally each year, and approximately 1.37 million individuals succumb to the disease (2) (3) (4) . Based on the histological classification, lung cancers are divided into 2 types: Non-small cancer lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for 85% of all lung cancer cases (5) . NSCLS includes a number of histological subtypes, including lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma (LCC). LUAD is one of the main subtypes of NSCLC (6) . Despite
Downregulation of HOXA3 in lung adenocarcinoma
and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis in-depth studies and significant progress being made in lung cancer treatment in recent decades (7) (8) (9) (10) , comprehensive clinical evaluation and in-depth molecular mechanistic studies are still required. Therefore, further investigations of the pathological mechanisms of NSCLC are warranted. Thus, the screening of novel functional genes and targets in NSCLC may provide basic data and a preliminary theoretic basis for further studies on the pathogenesis of NSCLC. The homeobox (HOX) gene family is composed of 39 genes. These genes play critical roles in normal embryonic development by encoding transcription factors. The HOX gene family is divided into 4 groups: HOXA, HOXB, HOXC and HOXD. These genes localize to different chromosomal regions. The human HOXA gene cluster localizes to chromosome 7. There are 12 genes, including HOXA1 to HOXA11 and HOXA13 (11) (12) (13) . The HOXA gene cluster plays important roles in colorectal cancer, leukaemia, pancreatic cancer, oral squamous cell carcinoma and lung cancer (14) (15) (16) (17) (18) . For HOXA3, only one study suggests that it nat be used as a biomarker of LUAD. This study was conducted by Daugaard et al (19) . These researchers used a DNA methylation microarray to compare the genome-wide methylation patterns between tumour and tumour-adjacent lung tissues from 4 patients with LUAD and identified 74 differential methylation regions (DMRs). Through methylation sensitive-high resolution melting (MS-HRM) analyses, 18 DMRs were selected for validation in 52 LUAD tissues and 32 cancer-adjacent lung tissues. Finally, this study confirmed and validated 15 DMRs, including HOXA3, that could be used as biomarkers of LUAD (19) . However, studies on the clinical significance and regulatory mechanisms of HOXA3 expression in NSCLC are still lacking. Therefore, further studies are urgently required to examine HOXA3 expression in NSCLC and to investigate the potential regulatory mechanisms in order to provide new insight into the pathogenic mechanisms of NSCLC.
In this study, we used reverse transcription-quantitative PCR (RT-qPCR) to detect HOXA3 expression in NSCLC and normal lung tissues. HOXA3 expression in NSCLC was validated using the Gene Expression Profiling Interactive Analysis (GEPIA) database. In addition, informatics analysis methods, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI), were performed to investigate the potential molecular mechanisms of action of HOXA3. Furthermore, the potential target microRNAs (miRNAs or miRs) of HOXA3 were predicted using miRWalk2.0. The expression levels of miRNAs were validated using the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TGCA) databases. The study design is presented in Fig. 1 .
Materials and methods
Clinical samples. A total of 55 tissues of cases of clinical NSCLC and cancer-adjacent lung tissues were collected (from January, 2012 to February, 2014) at the Department of Pathology of The First Affiliated Hospital of Guangxi Medical University (Nanning, China). Among these 55 patients, 32 cases were diagnosed with LUAD, and 23 cases were diagnosed with LUSC. There were 41 men and 14 women. Patients were 23-90 years of age with a mean age of 56.9 years. Among these 55 cases, tumours in 39 cases were larger than 3 cm. Table I summarizes the detailed clinicopathological data of all the patients. Samples were fixed in formalin and embedded in paraffin. This research programme was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. All participants signed informed consent forms. All samples were diagnosed by 2 pathologists (G.C. and D.-M.W.) independently using the double-blind method.
Detection of HOXA3 expression by RT-qPCR. HOXA3 expression in NSCLC samples was detected by RT-qPCR which was performed as previously described (20) (21) (22) . Total RNA was extracted from the tumour and cancer-adjacent normal tissues using the RNeasy reagent (Qiagen, Shanghai, China). The RNA Figure 1 . Flow chart of the study design of this study. Table I . The association of between HOXA3 mRNA expression in NSCLC tissues and patient clinicopathological characteristics based on RT-qPCR detection. concentration was measured using NanoDrop2000 (Thermo Fisher Scientific, Wilmington, DE, USA). Total RNA was reverse transcribed (10 µl reaction system) using a reverse transcription kit (ABI, Life Technologies, Carlsbad, CA, USA) to obtain cDNA for RT-qPCR. SYBR-Green (Shanghai GeneCore BioTechnologies Co., Ltd., Shanghai, China) was used to perform RT-qPCR and the distinctiveness of the PCR product was differentiated based on melting curve (23) (24) (25) (26) . RT-qPCR was carried out using the following conditions: preheating for 10 min at temprature 95˚C; and then repeating 40 cycles in temperature 95˚C for 15 sec and 60 sec at 60˚C. The primer sequences of HOXA3 were as follows: Upstream, TCATTTAAGAGCGCCTGGACA and downstream primer, GAGCTGTCGTAGTAGGTCGC. Using GAPDH as an internal reference gene and the primer sequence were as follows: Upstream, 5'-TGGTCCCTGCTCCTCTAAC-3' , downstream primer, 5'-GGCTCAATGGCGTACTCTC-3'. The relative expression level of HOXA3 in this study was calculated using the 2 -ΔΔCq (27) formula (28, 29) .
HOXA3 expression t-test of data
Retrieval of TCGA data. GEPIA (http://gepia.cancer-pku.cn/) is a visualization website based on TCGA data and contains differential gene expression between cancer and non-cancer, and analysis of the association between gene expression and overall survival (OS) or disease-free survival (DFS) and clinical stages (Stage). Survival analyses were performed using the log-rank test (also known as Mantel-Cox test) for hypothesis tests and calculation of the hazard ratio (HR) and 95% confidence interval (95% CI). Keywords, such as 'HOXA3', 'LUAD' and 'LUSC', were searched in GEPIA to retrieve data of the differential expression of HOXA3 in NSCLS, LUAD, LUSC and normal lung tissues, as well as information regarding the association between HOXA3 and clinical stages and prognostic survival. The keywords 'lung' and 'HOXA3' were searched in the cBioPortal (http://www.cbioportal.org/) website to retrieve genetic alteration data of HOXA3 in LUAD and LUSC. Data were obtained from microarray detection and RNA sequencing. In addition, DNA methylation data in LUAD and LUSC were downloaded from the Cancer Genome Atlas (TCGA: https://cancergenome.nih.gov/abouttcga/overview) database. HOXA3 methylation data in LUAD and LUSC were screened.
HOXA3 co-expression genes. To investigate the intrinsic mechanisms of HOXA3 expression in NSCLC tissues, we acquired HOXA3-associated co-expression genes from the MEM (http://biit.cs.ut.ee/mem) and cBioPortal databases. In MEM, when the score/P-value was smaller, the association between that gene and HOXA3 was more significant. The results of 2 gene probes were extracted from MEM based on a P-value <0.0001, and the results were used for intersection. On the other hand, Pearson's correlation analysis was performed in cBioPortal to calculate the correlation between co-expression genes and HOXA3. When the absolute value of the Pearson's correlation coefficient was larger, the correlation was stronger. This study selected genes with an absolute value of the Pearsons' correlation coefficient >0.3 in NSCLC, LUAD and LUSC. Finally, the intersection results between MEM and cBioPortal were obtained and used for further analyses.
The overlapping genes were confirmed using a Venn diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/).
Bioinformatics analyses. In this study, we used bioinformatics analyses to preliminarily investigate the molecular mechanisms of action of HOXA3 in NSCLC. The final overlapping genes in MEM and cBioPortal were used for GO and KEGG analyses in David v6.7 (http://david.abcc.ncifcrf.gov/) to elucidate the enrichment of genes in biological processes and signalling pathways. PPI analyses were performed in STRING v10.5 (https://string-db. org/cgi/input.pl?input_page_show_search=on&UserId=HJJhhN v8hYyf&sessionId=Ce1Dx9pYDluc) to validate the protein interaction association to hypothesize the pathways through which HOXA3 carries out its functions in NSCLC. The construction of the functional network was performed using Cytoscape 3.5.0 software and ClueGO plugin.
Prediction and preliminary validation of target miRNAs of HOXA3. The prediction of target miRNAs of HOXA3 was performed in miRWalk2.0 (http://zmf.umm.uni-heidelberg. de/apps/zmf/mirwalk2/). miRWalk2.0 contains 12 on-line target gene prediction tools: Pictar2, miRWalk, miRMap, DIANA microT v4, PITA, miRanda, RNA22, mirBridge, miRDB, RNAhybrid, miRNAMap and TargetScan. miRNAs that were present in >8 software results were used as candidate miRNAs for further analyses.
The microarray results of differentially expressed miRNAs in lung cancer were searched in the GEO database and downloaded. The following search formula was employed: (lung OR pulmonary OR respiratory OR bronchi OR bronchioles OR alveoli OR pneumocytes OR 'air way') AND (cancer OR carcinoma OR tumor OR neoplas* OR malignan* OR adenocarcinoma) AND (microRNA OR miRNA OR 'micro RNA' OR 'small temporal RNA' OR 'noncoding RNA' OR ncRNA OR 'small RNA'). We included microarray data containing expression data of miRNAs in lung cancer tissues and normal lung tissues and a sample number >3 into this study. Microarray data that did not conform to this condition were excluded. In addition, miRNA expression data for the LUAD, LUSC and normal lung tissues were extracted from the TCGA database. The mean value ± standard deviation (means ± SD) of the expression of potential target miRNAs in tumour and non-tumour tissues in each microarray was calculated. The random effects model was used to calculate the standardized mean difference (SMD) in STATA 2.0 software to evaluate the expression trend of miRNAs in NSCLC and plot the forest plot. In addition, analyses using the sROC method were performed to further validate the expression trend of miRNAs in NSCLC.
Statistical analyses. Statistical analyses of the experimental data were performed using SPSS 22.0 software (IBM, New York, NY, USA). The HOXA3 expression levels detected by RT-qPCR were expressed as the means ± SD and the Mann-Whitney test was used to determine significance. The normal distribution was determined using the singlesample K-S test. The comparison of the association between the HOXA3 expression level and the patient clinicopathological characteristics, and the comparison of mean values of 2 factors were performed using the independent sample t-test when variances were homogeneous. When variances were not homogeneous, rank sum statistical analysis was performed. The comparison of the mean values of multiple factors was performed using one-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test, with a default P-value of 0.05. The differences in HOXA3 expression levels between the NSCLC and normal lung tissues were further validated using the calculation of the area under the ROC curve. The Kaplan-Meier curve method was performed to analyse the association between the HOXA3 expression level and NSCLC patient survival. Pearson's correlation analysis was used to calculate the correlation between two genes. GraphPad Prism was used to generate the scatter plot. Meta-analysis of target miRNAs in NSCLC and normal lung tissues was performed using the STATA 12.0 software. P<0.05 in all analytic results indicated that the differences exhibited statistical significance.
Results

HOXA3 expression in NSCLC.
For NSCLC, the HOXA3 expression level in the cancer tissues was 0.11±0.14 and the fold change (FC), 0.60 (FC is the fold change of HOXA3 expression in tumour and non-tumour adjacent tissue). Compared with the normal lung tissues (0.19±0.20, P=0.006), HOXA3 expression was significantly decreased (P=0.006; Fig. 2A ). The median of the HOXA3 level was 0.06 and the FC, 0.5 (control, 0.12; P=0.008). The area under the ROC curve (AUC) of low HOXA3 expression in NSCLC was 0.65 (95% CI: 0.54, 0.76; P=0.008, Fig. 2B ). Therefore, a low HOXA3 expression may have some value in the occurrence of NSCLC. A low HOXA3 expression was not significantly associated with the clinicopathological characteristics (Table I ). In addition, in LUAD, the mean expression level of HOXA3 was 0.13±0.17 and the FC, 0.55. HOXA3 expression was significantly decreased in LUAD compared with the canceradjacent normal tissues (0.24±0.24, P=0.023) ( Fig. 2C and Table I ). The median of the HOXA3 level was 0.08 and the FC, 0.62 (control, 0.13; P=0.034). The AUC of downregulated HOXA3 expression in LUAD was 0.66 (95% CI: 0.52, 0.80; P=0.035) (data not shown). Further analyses revealed that the HOXA3 level in smokers (0.06±0.04) was reduced compared with that in non-smokers (0.186±0.20, P=0.025) ( Fig. 2D and Table I ). The AUC of downregulated HOXA3 in the smoking group was 0.70 (95% CI: 0.51, 0.89; P=0.069) (data not shown). The combination of the above-mentioned data analyses demonstrated that the downregulation of HOXA3 expression in LUAD was significant. In addition, HOXA3 expression in LUAD may be associated with smoking, but did not exhibit a significant association with other clinicopathological characteristics. The analyses of the LUSC group alone revealed that HOXA3 expression differed significantly between the cancer tissues and non-cancer tissues (cancer, 0.09±0.08 vs. control, 0.12±0.09, P=0.034, FC, 0.72) ( Fig. 2E and Table I ). The median of the HOXA3 level was 0.06 and the FC, 0.5 (control, 0.12; P=0.113). The AUC of the low HOXA3 level in the LUSC group was 0.64 (95% CI: 0.47, 0.81; P=0.113) (data not shown). The low expression of HOX3A in LUSC was not significantly associated with disease progression.
In addition, the GEPIA data revealed that HOXA3 expression in LUAD (483 cases) was also significantly decreased compared with the normal lung tissues (347 cases) and exhibited a low expression trend in LUSC (LUSC, 486 cases; normal, 338 cases) (Fig. 3A) . These results were consistent with the results of RT-qPCR. However, the association between the HOXA3 expression level and the pathological stage did not exhibit an obvious pattern (Fig. 3B) . We also acquired information regarding the association between the HOXA3 expression level and the survival of patients with NSCLC, LUAD and (Fig. 4A,  panel a) . Thus, a low HOXA3 expression may be a protective factor of OS in patients with NSCLC. However, further analysis demonstrated that HOXA3 was not significantly associated with the DFS of patients with NSCLC (Fig. 4A,  panel d) . The analyses of OS in the LUAD group alone demonstrated that patients with a high HOXA3 expression exhibited an HR of 1.4 (P=0.042) (Fig. 4A, panel b) , suggesting that a high HOXA3 level may be a risk factor for the prognosis of LUAD. However, the HOXA3 expression levels did not exhibit obvious predictive values as regards the DFS of patients with LUAD (Fig. 4A, panel e) . In addition, the association between HOXA3 and the prognosis of patients LUSC was not statistically significant (Fig. 4A , panels c and f), and this may require further investigation.
Furthermore, based on the microarray and RNA sequencing technologies, the sequencing results of 520 patients with LUAD revealed that the genetic alteration rates of HOXA3 were 5% (24/520) and 11% (59/520). In addition, the sequencing results of 504 patients LUSC suggested that the genetic alteration rates of HOXA3 were 5% (25/504), 7% (35/504) and 4% (18/504). Although the genetic alternation rates obtained using different methods differed, the final results all confirmed that HOXA3 harboured genetic alterations in the LUAD and LUSC populations (Fig. 4B) . (Table II) . Compared with the normal tissues (NSCLC, 0.43±0.11; LUAD, 0.44±0.11; LUSC, 0.42±0.11), these levels were all significantly upregulated.
HOXA3 co-expression genes. Based on MEM, 11,488 and 4,730 HOXA3 co-expression mRNA genes detected by 2 independent gene probes were obtained. The intersection between the results of 2 gene probes was collected, and a total of 1,709 more convincing co-expression mRNA genes were extracted. The data from cBioPortal revealed 3,600 and 2,676 co-expression mRNA genes in the NSCLC group and the LUAD group, respectively. Finally, the search results of the NSCLC group and the LUAD group in MEM and cBioPortal were processed using the crossing method (data not shown). In total, 293 and 213 genes were obtained, respectively, for further analysis.
Bioinformatics analyses. GO and KEGG analyses were performed on 293 and 213 genes in DAVID, and PPI network analyses were performed in STRING. The results from GO analysis revealed that genes in the NSCLC group mainly participated in biological processes, such as the regulation of cell migration; the regulation of apoptosis; and the regulation of programmed cell death; cellular components, such as insoluble fraction, membrane fraction, and extracellular matrix; and molecular functions, such as sequence-specific DNA binding, enzyme activator activity, and phosphatidylinositol-3,4,5-trisphosphate binding (Figs. 6 and 8A-C, and Table III) . The results of KEGG pathway analyses suggested that HOXA3 may be involved in the functional regulation of 22 signalling pathways in the NSCLC group. The most important pathways were focal adhesion, pathways in cancer, and the TGF-β signalling pathway (Figs. 7 and 8D , and Table IV) . In addition, genes in the LUAD group mainly participated in biological processes, such as the regulation of cell migration, regulation of apoptosis and the regulation of programmed cell death. Significant enrichment also occurred in cellular components and molecular functions; for example, insoluble fraction and membrane fraction in cellular components and sequence-specific DNA binding and enzyme activator activity in molecular functions (Figs. 9 and 11A-C, and Table V) . The analytical results in the LUAD group suggested that HOXA3 may be involved in the biological regulation of 15 signalling pathways. Of these pathways, the most significant pathways were focal adhesion and ECM-receptor interaction (Figs. 10 and 11D , and Table VI) . In PPI analyses, 278 interaction nodes were obtained in the NSCLC group (Fig. 12A) . The genes with the top 10 overall scores are presented in Table VII . The results of interaction network analyses demonstrated that MAPK1, EGFR, DCN and CFTR represented key genes in these networks. In addition, genes enriched in 'Focal adhesion' were used for PPI analyses, and a total of 13 interaction nodes were obtained (Fig. 12B ). The genes with the top 10 overall score are presented in Table VIII . The results suggested that MAPK1, EGFR, TNC and COL1A1 were key genes in this pathway. PPI analyses were also performed on genes in the LUAD group, and the results generated 129 protein interaction nodes (Fig. 13 ). The nodes with the top 10 overall scores are presented in Table IX . The protein interaction network suggested that MAPK1, EGFR, CFTR and GLI3 were key nodes in these interaction networks. Genes in the LUAD group that were enriched in 'Focal adhesion' were used for PPI analyses, and 14 protein interaction network nodes were also obtained. The result was the same as that for the NSCLC group. MAPK1, EGFR, TNC and COLIA1 were key genes in these pathways (refer to Fig. 12B and Table X ). Analytic results revealed that genes in the NSCLC and LUAD groups all participated in the regulation of the 'Focal adhesion' pathway. MAPK1 and EGFR played key roles in NSCLC and LUAD, whereas MAPK1, EGFR, CFTR and GLI3 represented key genes in the 'Focal adhesion' pathway. Therefore, these 4 genes were analysed further. Based on TCGA data, the results of Pearson's correlation analysis revealed that the 4 genes, EGFR, MAPK1, COL1A1 and TNC, all exhibited a potential positive correlation with HOXA3 expression in NSCLC (Fig. 14) . In the LUAD group, only COL1A1 and TNC exhibited a possible positive correlation with HOXA3 ( Fig. 15C and D) .
HOXA3 methylation level t-test of data
Prediction and preliminary validation of HOXA3 target miRNAs. HOXA3 had 3 target miRNAs that passed the target prediction. Based on GEO microarray search and TCGA database, the random effects model was used for meta-analyses of the expression of these 3 miRNAs in NSCLC tissues. The results revealed that the expression of hsa-miR-372-3p was significantly increased in the NSCLC and LUAD tissues, but only exhibited an increasing trend in the LUSC tissues (NSCLC P<0.001, LUAD P=0.017, and LUSC P=0.243) (Fig. 16A ). In addition, hsa-miR-372-3p and HOX3A had 1 fragment of complementary sequences of '3'CGUGAA5'-3' GCACUU-5'' (Fig. 16B) . Furthermore, the sensitivity and specificity of miR-372-3p expression in NSCLC were examined using the sROC method. The results suggested that the optimal sensitivity and specificity of a high miR-372-3p expression in the NSCLC group were SENS, 0.71 (0.57, 0.83) and SPES, 0.65 (0.52, 0.76), respectively, and (Fig. 16C and D) .
Discussion
This study used qPCR detection and TCGA RNA-seq data to confirm that HOXA3 expression was significantly downregulated in LUAD tissues. The downregulation of HOXA3 may be closely associated with a more favourable prognosis of LUAD. In addition, the TCGA data indicated that HOXA3 harboured genetic alterations in 11-55% of LUAD tissues, and the methylation level of HOXA3 in LUAD tissues was significantly upregulated. Combined with the TCGA data, the upregulation of the HOXA3 level in LUSC was not significant. Therefore, we paid more attention to the clinical significance and molecular mechanisms of action of HOXA3 in LUAD. Through the collection of co-expression genes and GO and KEGG analyses, the preliminary results revealed that HOXA3 may play important roles in LUAD through the regulation of focal adhesion and ECM-receptor interaction signalling pathways. Furthermore, through the prediction of HOXA3 target miRNAs and meta-analyses of target miRNA expression based on the GEO microarray and TCGA data, the results confirmed that the expression of miR-372-3p that had complementary sequences with HOXA3 was significantly increased in LUAD tissues. There have been some studies of the association between the HOXA3 level and tumours. For example, Zhang et al (30) demonstrated that HOXA3 exhibited a high expression in both colorectal cancer tissues and cell lines. Shen et al (31) assessed the association between HOX family genes and nasopharyngeal carcinoma and demonstrated that HOXA3 expression was also upregulated. Kuasne et al (32) suggested that HOXA3 exhibited a low expression in penile carcinoma. At least to the best of our knowledge, only 1 methylationrelated study on the association between HOXA3 and LUAD has been reported (19) . This study, to the best of our knowledge, was the first to detect HOXA3 mRNA expression in LUAD. Combined with qPCR detection and TCGA data, we confirmed that HOXA3 expression was downregulated in LUAD tissues, and a low HOXA3 expression may play a important role in LUAD.
The investigation of the association between HOXA3 and tumour progression has demonstrated that a high HOXA3 expression is associated with low survival rates in colon cancer (33) . In penile carcinoma, a low HOXA3 expression was found to be associated with a poor prognosis (32) . However, the association between HOXA3 and the progression of nasopharyngeal carcinoma has not been studied in depth (31) . Our analyses of HOXA3 expression in all pathological stages of LUAD did not exhibit an obvious pattern. The survival analyses demonstrated that patients LUAD with a low HOXA3 expression had a better OS. Therefore, we hypothesized that the downregulation of HOXA3 expression may be an independent protective factor in LUAD. Furthermore, based on the microarray and RNA Seq data in TCGA, we preliminarily revealed that HOXA3 harboured a certain level of genetic alterations in LUAD tumour tissues. Thus, we would like to acquire more information for further validation. However, relevant studies are currently lacking, and literature reports are not available, at least to the best of our knowledge. As regards gene methylation, Kuasne et al performed genome-wide methylation studies on penile carcinoma and confirmed that 8 genes, including HOXA3, exhibited high methylation levels (32) . In a validation study of epigenetic biomarkers in LUAD, Daugaard et al (19) performed genomewide methylation microarray sequencing on 4 cases of LUAD tissues and normal cancer-adjacent lung tissues to screen differentially methylated genes in LUAD. They selected the 18 most significantly differentially methylated genes, including HOXA3, for validation in 52 samples. The methylation level of HOXA3 significantly increased (19) . This study acquired HOXA3 methylation data from the TCGA database to perform analyses. The results suggested that the HOXA3 methylation level was significantly increased in LUAD tissues. This finding was consistent with the results in literature reports. Combined with HOXA3 mRNA expression levels in LUAD, the function of HOXA3 in LUAD may be associated with the increase in the methylation level. In addition, the study by Daugaard also demonstrated that the increase of HOXA3 methylation was even more evident in patients with tumour metastasis; however, its association with the prognostic survival rates in LUAD patients has not been elucidated (19) . Despite the results of this study, sufficient evidence is not yet available to confirm the association between the methylation level of HOXA3 and LUAD progression. Thus, further studies are required for confirmation. As regards studies on the association between DNA methylation and mRNA expression, Kuasne et al (32) performed qPCR detection to demonstrate that genes with high methylation levels exhibited a low expression in penile carcinoma. These results confirmed that the methylation level and mRNA expression exhibited a negative correlation (32).
Zhang et al performed cell experiments to confirm that a group of genes (S100P, GDA, WISP2, LOXL1, TIMP4, ICAM1, CLMP, HSP8, GAS1 and BMP2) exhibited a downregulated mRNA expression through high methylation levels to induce drug resistance in NSCLC (34) . Jin et al demonstrated that 19 genes mediated the downregulation of mRNA expression through the increase in upstream methylation levels in LUAD (35) . This study confirmed the low expression of HOXA3 in LUAD and the increase in the methylation level.
Based on these findings, we hypothesized that HOXA3 methylation has a negative regulatory association with mRNA expression and plays critical roles in tumour development and progression.
To investigate the underlying molecular mechanisms, GO and KEGG analyses were performed to compare the enrichment of HOXA3 co-expression genes between the NSCLC group and the LUAD group. The results demonstrated that the enrichment conditions in biological processes, cellular components, and molecular functions were basically the same. Some differences in the KEGG signalling pathways were noted. The LUAD group was more concentrated on the focal adhesion and ECM-receptor interaction pathways. HOXA3 may carry out its regulatory functions in LUAD through participation in these 2 signalling pathways. The focal adhesion signalling pathway is a critical pathway to activate focal adhesion kinase (FAK). Kinases activated by this pathway mainly mediate a variety of cellular metabolic processes, including cell metastasis, growth factor signal transduction, cell survival, cell cycle progression, and cell movement, and are closely associated with the development of malignant tumours (36) (37) (38) . Currently, there are literature reports on using FAK as a novel potential biological target to investigate targeted therapy of NSCLC (39, 40) . The ECM-receptor interaction signalling pathway mediates the expression of enriched genes and regulates functions of these genes to promote tumour cell proliferation and migration and participate in tumour metastasis and infiltration (41, 42) . In NSCLC unrelated to smoking, the ECM-receptor interaction signalling pathway plays a critical role (43) . The above-mentioned 2 signalling pathways significantly influence the development and progression of human malignant tumours and act as the bridge between abnormal gene expression and malignant tumour development.
Therefore, in this study, we performed PPI analyses on genes enriched in the focal adhesion and ECM-receptor interaction In this study, we also performed meta-analyses to confirm that the expression of the predicted miR-372-3p was upregulated in LUAD. Complementary sequences were noted between miR-372-3p and HOXA3. Combined with qPCR detection, HOXA3 and miR-372-3p expression exhibited a negative correlation trend in LUAD. The results of a literature search demonstrated that miR-372-3p was highly expressed in both testicular cancer and LUSC. miR-372-3p promotes cell growth and migration in LUSC through the downregulation of the target gene FGF9 (48, 49) . Therefore, based on results of this study and those of studies in the literature, we hypothesized that the downregulation of HOXA3 expression in LUAD tissues may be associated with the increase in miR-372-3p expression and HOXA3 may carry out its function through the targeted upregulation of miR-372-3p. However, this hypothesis needs to be validated using various experiments.
In conclusion, combined with the RT-qPCR detection results and data from the TCGA and GEO databases, we confirmed that HOXA3 expression was downregulated in LUAD tissues and exhibited a certain level of genetic alteration. The functions of downregulated HOXA3 in tumour progression and a poor prognosis of patients with LUAD may be associated with increases in the methylation level. Furthermore, HOXA3 may collaborate with co-expression genes, such as TNC and COL1A1, to regulate the focal adhesion and ECM-receptor interaction signalling pathways together or upregulate miR-372-3p to promote its carcinogenesis function. These study results provide true and reliable experimental data and rigorous molecular theories for further studies on the molecular mechanisms of HOXA3 in LUAD. 
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